Type-1 Diabetes Clinical Trials News

This blog posting reports on the results of Avotres recent phase-I clinical trial into AVT001 and the

This clinical trial tested whether long-term daily treatment with Remygen®, an oral drug developed by

I'm going to start using generative AI (what people call "chatbot" technology) to help

This blog post reports on some news that I consider exciting, for at least two different reasons:

TIX100 is a protein which inhibits the action of TIXNP (thioredoxin-interacting protein). It is being

This is the most fun I have had writing a blog in a long time. It is not often I can blog about

Denosumab is a monoclonal antibody, which is already approved for several bone related diseases and

Last year, at the start of the year, I published a blog of four research projects I was looking

Normally, sometime in October, I write a summary of all the clinical trials funded by JDRF. However,

Fenofibrate (also spelled Phenofibrate) is commonly prescribed for high cholesterol and high

The company Encellin has started a Phase-I clinical trial to test ENC-201-CED an encapsulated beta

There are two good reasons to test Frexalimab as a cure or treatment for Type-1 Diabetes (T1D). The

If you've been reading news recently you might have seen headlines like these: Stem cells reverse

Rituximab is FDA-approved to treat several autoimmune diseases, including Rheumatoid Arthritis (RA).

(Note: JAKPOT is a name of at least two different clinical trials. If you are reading about a French

BMF-219 is a drug that inhibits Menin, a protein. Menin's functions in cells are not fully

Fenofibrate (also spelled Phenofibrate) is commonly prescribed for high cholesterol and high

Siplizumab (MEDI-507, TCD601) is an monoclonal antibody which targets CD2 cells in the immune system.

This whole blog posting is very US (and US politics) focused, but the issues are similar in other

Diamyd Update Part 2: JDRF Flexibilty In Funding and Diamyd In More People My previous blog posting:

Levicure is a startup which is currently raising money to fund a phase-II trial for a combination

This clinical trial represents an attack on T1D slightly different than anything I've blogged on

Baricitinib (trade name Olumiant) is a drug which targets the immune system, and is already approved

At the start of a new year, some bloggers write a posting on the year that was, and a some write a

This is my first update on the Diamyd company in many, many years. It is focused on their DIAGNODE-3

In this blog I'm going to report on three different clinical trials involving transplantation.

Teplizumab (sold as Tzield) was recently approved for use in people at-risk of diagnosis for T1D. At

In the US, we are in the "Walking Season" when JDRF (Juvenile Diabetes Research Foundation)

Difluoromethylornithine (DFMO), also known as Eflornithine, is FDA approved since 1990 as an

I've been blogging on research aimed at curing type-1 diabetes for over 15 years, and in that